4.1 Article

Clinical Validity of the Mattis Dementia Rating Scale-2 in Parkinson Disease With MCI and Dementia

Journal

JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
Volume 25, Issue 2, Pages 100-106

Publisher

SAGE PUBLICATIONS INC
DOI: 10.1177/0891988712445086

Keywords

Parkinson disease; mild cognitive impairment; dementia rating scale; dementia; screening; validity

Funding

  1. Canadian Institutes of Health Research (CIHR)
  2. Alzheimer Society of Canada
  3. Fonds de la Recherche en Sante du Quebec
  4. CIHR (Institute of Aging)

Ask authors/readers for more resources

The utility of the Mattis Dementia Rating Scale 2 (MDRS-2) in screening for dementia in Parkinson disease (PD) is well documented. However, little is known about its sensitivity to mild cognitive impairment in PD (PD-MCI). This study sought to document the validity of the MDRS-2 for diagnoses of PD-MCI and dementia in PD (PDD). Twenty-two healthy controls (HCs), 22 PD-MCI, and 16 PDD were compared on each MDRS-2 subscales and MDRS-2 total standard scores. Patients with PDD performed significantly worse than the other groups (all Ps < .05) on the MDRS-2 total and on all subscales, except attention. PD-MCI had significant lower scores than HCs on the MDRS-2 total and on initiation/perseveration and memory subscales. The optimal cutoff score for PD-MCI diagnosis was <= 140/144 and <= 132/144 for PDD. These findings suggest that MDRS-2 is a useful tool to identify dementia but that there might be a ceiling effect in the MDRS-2 cutoff score to diagnose MCI in PD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available